ImmuneOnco Biopharmaceuticals has announced the initiation of a Phase II clinical trial for its investigational drug, IMM27M, following encouraging outcomes from its Phase I study in patients with estrogen receptor-positive advanced breast cancer. The Phase I trial results, showcasing a 25% overall response rate and a 75% disease control rate, pave the way for further evaluation of IMM27M's potential.
The Phase I study, designed to assess the safety and tolerability of IMM27M, reported no dose-limiting toxicities at the highest dose tested. This favorable safety profile is crucial as the drug advances into larger, more comprehensive trials. The initiation of the Phase II trial marks a significant step forward in ImmuneOnco's efforts to develop novel cancer treatments.
Breast cancer is a prevalent malignancy worldwide, with a substantial proportion of cases being estrogen receptor-positive. While endocrine therapies are often effective initially, many patients eventually develop resistance, leading to disease progression. IMM27M is being developed to address this unmet medical need by providing an alternative or complementary treatment option for patients with advanced estrogen receptor-positive breast cancer. The specifics of the Phase II trial design, including patient population size and endpoints, were not disclosed in the announcement.
The advancement of IMM27M into Phase II trials represents a noteworthy milestone for ImmuneOnco and potentially offers hope for patients with advanced breast cancer who have limited treatment options.
